It’s been nearly a year since President Donald Trump signed an executive order establishing a “strategic Bitcoin reserve” and vowed that the government would never sell the cryptocurrency on his watch ...

Artificial intelligence is entering the era of self-improvement. On Thursday afternoon, OpenAI released a new cutting-edge coding model that the company said assisted in its own creation.

Ricursive Intelligence, a startup building an AI system to design and automatically improve AI chips, has raised $300 million at a $4 billion valuation. The company said Monday the round was led by ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the overlooked penny stocks to invest in. On January 12, Alec Stranahan, an analyst at Bank of America Securities, maintained a Hold rating on ...

Recursion Pharmaceuticals owns the largest supercomputer in the pharmaceutical industry. However, Eli Lilly is starting to build one that could be even more powerful once it's completed. With its ...

Recursion Pharmaceuticals remains a high-cash-burn, premium-valued biotech with unproven clinical success despite a recent 47% rally. RXRX's next 18 months are catalyst-rich, but key pipeline assets ...

3I/ATLAS imaged by the Two-Meter Twin Telescope in the Canary Islands — showing a sunward jet nearly 6,000 km long. According to Sereda’s October 13 report, the object emitted light flashes in a ...

Long-Term Support release, with features ranging from structured concurrency and compact object headers to ahead-of-time method profiling and JFR CPU-time profiling on Linux, is now generally ...

This AI company isn't yet living up to the hype. Let's discuss Recursion Pharmaceuticals' performance over the past four years and whether the company can deliver solid returns in the future. It can ...

Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is expected to beat earnings when it reports second-quarter 2025 results on Aug. 5 ...